Search company, investor...

Plasmapp

plasmapp.co.kr

Founded Year

2015

Stage

Line of Credit | Alive

Total Raised

$28.1M

Last Raised

$8.32M | 3 yrs ago

About Plasmapp

Plasmapp is a manufacturing company specializing in plasma technologies. The company has developed a plasma sterilizer for medical tools. This technology is made possible by its STERPACK packaging pouches, which feature a fast sterilization cycle time and allow sterilization to be low-temperature. In addition to its medical sterilization devices, Plasmapp has also developed the Linear Jet Plasma Source (LJPS), a device used to diffuse the glow-like discharge in manufacturing lines for rechargeable batteries, and that can even be used with air or nitrogen gas applied.

Headquarters Location

83 Jukdong-ro, Yuseong-gu

Daejeon, 34127,

South Korea

+82) 42-716-2115

Missing: Plasmapp's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Plasmapp's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Plasmapp

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Plasmapp is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

8,600 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,901 items

Plasmapp Patents

Plasmapp has filed 13 patents.

The 3 most popular patent topics include:

  • Drug delivery devices
  • Hygiene
  • Dosage forms
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/4/2020

10/11/2022

Grant

Application Date

12/4/2020

Grant Date

10/11/2022

Title

Related Topics

Status

Grant

Latest Plasmapp News

Plasmapp to expand into new bioindustries with IPO on Kosdaq

Oct 5, 2022

Plasmapp to expand into new bioindustries with IPO on Kosdaq 바로가기 기자명 Marianne Chang 닫기 Plasmapp, a bio plasma technology company, said it would expand its research and development (R&D) platform to accelerate the development of its pipeline biomedical devices by going public on the Kosdaq market this month. Plasmapp CEO Lim You-bong presented the company's IPO strategy at 63 Building's conference room in Seoul on Wednesday. The company was founded at the lab of the Korea Advanced Institute of Science and Technology (KAIST)’s physics department in 2015. The biomedical device company specializes in low-temperature plasma sterilizers. Plasmapp will predict the demand of institutional investors' subscription on Oct. 5-6, and open the subscrition for retail investors on Oct. 12-13. Mirae Asset Securities is the underwriter. Through the IPO, the company plans to offer 1.771 million shares at 9,000 to 11,000 won per share to raise between 15.9 to 19.5 billion won ($13.7 million) with a majority stakeholder composition of 45.2 percent coming from venture capitalists. Plasmapp CEO Lim You-bong presented their business model for predicted revenue growth through original design manufacturing (ODM) and license and operating (L/O) contracts and non-recurring engineering (NRE) partnerships to facilitate the company’s transition from development to mass production. With this model, by 2025, its novel skin irritation treatment solution (STIMLINK-STIMMATE) and regenerative solution (ACTILINK-ACTIMATE) are expected to collectively generate profits accounting for 49.1 percent with the remaining 50.9 percent coming from its sterilization solution (STERLINK-STERMATE). A company official provides a demonstration of the existing products alongside the prototypes. Plasmapp also demonstrated the prototype models of these solutions, one of which is expected to be applied for skin regeneration to heal from post-surgical scarring and another special 3D printing technology for customized and biocompatible surgical implants with its patented plasma technology. Some of the major global companies they are collaborating with include BioHorizons, MegaGen and Smith+ Nephew to fully commercialize its prototypes by 2024. Plasmapp's three new prototype devices are displayed with an expected launch date in 2024. According to Markets and Markets, Plasmapp’s potential medical market expansion into 3D printed medical devices, robotic surgery, implantable IoT devices and novel material medical devices, as outlined by the CEO, is expected to have a cumulative market size of $154.4 billion in 2025. “Despite the slowing economy, we are happy to achieve this milestone and are confident that this IPO is the right step for the company to continue expanding our reach into new global medical markets.” CEO Lim said.

Plasmapp Frequently Asked Questions (FAQ)

  • When was Plasmapp founded?

    Plasmapp was founded in 2015.

  • Where is Plasmapp's headquarters?

    Plasmapp's headquarters is located at 83 Jukdong-ro, Yuseong-gu, Daejeon.

  • What is Plasmapp's latest funding round?

    Plasmapp's latest funding round is Line of Credit.

  • How much did Plasmapp raise?

    Plasmapp raised a total of $28.1M.

  • Who are the investors of Plasmapp?

    Investors of Plasmapp include Korea Technology Finance Corporation, Samsung Ventures, LB Investment, AI Angel Club, Stonebridge Ventures and 7 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.